Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced the appointment of Russ Belden as Acting Chief Commercial Officer.

Mr. Belden is a commercialization leader with over 33 years of senior leadership experience in the biotechnology industry, specializing in strategic marketing, sales management, sales training, and product development. Through his firm, Mr. Belden has worked with over 60 pre-clinical, early-launch phase therapeutics and molecular diagnostic companies.

“We are committed to driving our pipeline forward and are laser focused on advancing Trappsol^® Cyclo™ toward regulatory approval, most immediately for the treatment of NPC. As we commence our pre-commercialization activities, Russ’ experience, expertise and leadership will be pivotal as we drive forward our programs addressing indications with significant unmet need,” commented N. Scott Fine, CEO of Cyclo Therapeutics.

Mr. Belden began his career as an employee in Genentech’s SSF Commercial organization, where he spent 16 years launching products/indications across multiple therapeutic areas, including the launch of their BioOncology franchise and moving to increasing roles of responsibility, ultimately as Director of Hematology Sales. Mr. Belden is the Founder, President & CEO of Bridge Consulting LLC, where he has worked with over 60 emerging biotech companies over the past 17 years. In addition to providing commercial assessments for companies ranging from preclinical to Phase 2, he has provided critical commercial leadership to Phase 3 emerging biotech companies as an interim Chief Commercial Officer (iCCO). Mr. Belden currently serves as the iCCO at three Phase 3 companies. He also serves as the Commercial Expert for the California Life Sciences Institute’s (CLSI) FAST program.

Mr. Belden added, “I am excited to be joining the Cyclo Therapeutics team at this pivotal time for the Company. I believe Trappsol^® Cyclo™ has significant potential to provide much needed patient benefit in Niemann-Pick diseases as well as other diseases. I look forward to leveraging my experience and expertise as the Company continues to drive towards commercialization.”

Mr. Belden received his BS in Pharmacy from the University of New York at Buffalo and completed graduate coursework in Marketing at the University of Texas at Dallas.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol^® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol^® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol^® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com.

Safe Harbor Statement

This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.